Merck extends all-important lung-cancer lead with phase 3 Keytruda combo win
admin 16th January 2018 Uncategorised 0Skittish investors grew increasingly concerned last year that Merck & Co. couldn’t replicate its Keytruda-chemo combo success in a phase 3 trial of previously untreated patients. But on Tuesday, the pharma giant silenced its doubters.
More: Merck extends all-important lung-cancer lead with phase 3 Keytruda combo win
Source: fierce